Congenital hearing loss (HL) is the most common sensory disorder in humans, affecting one in 1000 infants at birth. A high degree of genetic heterogeneity makes it difficult to screen for mutations in all known deafness genes in clinical applications. We have improved a genotyping microarray using the multiplex PCR-based allele-specific primer extension (ASPE) reaction and applied this method for the genetic diagnosis of congenital HL in Korea. Seven different mutations in the GJB2, SLC26A4 and mitochondrial 12S rRNA genes, which were identified on the basis of a previous study in a Korean population, were selected for the study. These genes were used to evaluate the accuracy of the microarray. The test for validation of the current version of HL genotyping micro-array was fully concordant with the results of DNA sequencing in which 51 subjects with non-syndromic HL were originally genotyped. Furthermore, the blind test of the genotyping microarray detected four different mutations in 10 out of 65 patients, and the accuracy of microarray was calculated as 98% (64/65). Therefore, our results suggest that this HL genotyping microarray will be useful in clinical applications for the genetic diagnosis of HL.
Introduction
Hearing loss (HL) is a genetically heterogeneous disorder. To date, >120 loci and 47 genes encoding proteins with a wide variety of functions have been identified as being involved in non-syndromic HL, and these numbers are increasing (Hereditary Hearing Loss Homepage; http://webh01.ua.ac. be/hhh). In spite of this large heterogeneity, mutations in the GJB2 gene, which encodes for connexin 26 (Cx26), lead to the most common form of congenital HL (1, 2) . The SLC26A4 gene is associated with a form of non-syndromic HL (DFNB4) and Pendred syndrome, and mutations in this gene may cause up to 5-10% of hereditary HL in diverse populations (3) (4) (5) . A number of different mutations in these genes have been described around the world, but certain mutations occur more frequently in particular populations. For example, the c.235delC mutation in GJB2 and the p.H723R mutation in SLC26A4 are the most common mutations in Korean and Japanese populations, indicating a specific ethnic bias (6) (7) (8) (9) (10) . Aside from these nuclear genes, which are responsible for non-syndromic HL, mutations in mitochondrial genes are also involved in the development of congenital HL (11) . In particular, the A1555G mutation in the 12S rRNA gene has been identified as the most prevalent mitochondrial mutation affecting HL (12) .
Microarray-based technology has been applied to detect multiplex mutations for the genetic diagnosis of Mendelian disorders with profound allelic heterogeneity (13) and for analyzing panels of commonly recurring mutations (14) . In terms of clinical application, this technology allows for efficient, reproducible multiplex genotyping of sequence variations at the single nucleotide level at low cost and is suitable for the genotyping of genetically heterogeneous conditions such as non-syndromic HL. In this study, we improved a genotyping microarray assay which was originally made in the previous study (15) and applied this method to the genetic diagnosis of congenital HL.
Materials and methods
Subjects. Genomic DNA from 51 subjects with non-syndromic HL, which was originally genotyped by DNA sequencing analysis, was used to validate the results obtained using the microarray. For the blind test of the microarray, 65 congenital HL patients were studied to test the efficiency of the HL genotyping microarray. All participants provided written informed consent of the protocol, which was approved by the Ethics Committee of Kyungpook National University Hospital.
Mutation panel and array design. Seven different mutations in the GJB2, SLC26A4 and mitochondrial 12S rRNA genes previously identified in a Korean population were selected for the genotyping microarray: the GJB2 p.V37I, p.R143W and c.235delC mutations; the SLC26A4 IVS7-2A>G, IVS9+3A>G and p.H723R mutations; and the mtDNA A1555G mutation (6, 7, (16) (17) (18) . A set of 14 probes with wild and mutant sequences was designed and printed on amine-coated glass slides (GAPSII slide cat# 40004, Corning, Acton, MA, USA) in triplicate using a MicroGrid Compact printer (BioRobotics, Apogent Discoveries, Hudson, NH, USA). The mutation probe was printed directly below its corresponding wild-type probe for each mutation, as shown in Fig. 1 . Each probe contained a 25-mer complementary ZipCode sequence (cZipCode) linked to a 10-mer spacer (CAGCCAAGT) at the 5'-end. The 10-mer-spacer was included to increase the specificity of hybridization and to permit quality control of the chip fabrication.
Multiplex polymerase chain reaction (PCR). Multiplex PCRs were performed in a total volume of 25 μl, containing 90 ng genomic DNA, 2X PCR master mixes (iNtRON Biotechnology, Korea) and 0.4 pmole of each primer (IDT, Skokie, USA). The primer sequences used to amplify each mutation, the multiplex combinations of PCR primers and the expected sizes of the PCR products are listed in Table I . All amplifications were performed according to the same protocol, consisting of denaturation at 94˚C for 2 min, followed by 30 cycles of denaturation at 94˚C for 30 sec, annealing at 57˚C for 30 sec and extension at 72˚C for 30 sec, followed by a final extension at 72˚C for 5 min. Five microliters of the multiplex PCR products were separated and visualized on a 2% agarose gel.
Allele-specific primer extension (ASPE) reaction and hybridization.
Allele-specific oligonucleotides, which were complementary to either the normal or mutant sequence, were designed for accurate discrimination of nucleotide changes at the designated position. Each oligonucleotide had its own unique ZipCode sequence at the 5'-end, which hybridized with the cZipCode probe on the microarray. The validated ZipCode sequences in the previous study (15) were selected for the experiment and each ZipCode sequence had a Tm of 61±2˚C and ΔG > -2, and each was linked to an allele-specific oligonucleotide sequence at the 5'-end.
ASPE reactions were carried out in a total of 20 μl, including 5 μl of multiplex PCR products, 5 μl of a specific primer mix, 5 μl of cy5-dUTP, and 1 unit of i-star Taq DNA polymerase (iNtRON, Korea). The reaction mixture was incubated at 94˚C for 5 min followed by 30 cycles of 94˚C for 30 sec, 60˚C for 1 min and 72˚C for 1 min. The 20 μl of ASPE reaction products were pooled and purified using a PCR purification kit (Qiagen, Hilden, Germany) according to the protocol provided by the manufacturer. The fragments were eluted in 20 μl of H 2 O.
A quantity of 20 μl of the pooled ASPE products was suspended in 50 μl of hybridization buffer (5X SSC, 0.1% SDS, 25 mg/ml Human HybMasker DNA, 25% formamide, 0.5 mg/ml poly A, 10% dextran sulfate). After heating for 5 min at 95˚C and chilling on ice, the hybridization mixture was applied to a microarray slide for 30 min at 45˚C, washed once at 50˚C in 2X SSC, 0.1% SDS for 10 min and washed four times at room temperature in 0.1X SSC for 1 min per wash.
Data analysis. The microarray was scanned in a GenePix 4000B instrument (Molecular Devices Corp., Sunnyvale, CA, USA), and the fluorescence intensities were analyzed using GenePix Pro 6.0 software. The genotype index (GI) was calculated as described previously (15, 19) and the GI value was represented from the average of triplicate spots. An outline of the HL genotyping assay is presented in Fig. 2 . 
Multiplex combinations of PCR primers and the expected sizes of PCR products
----------------------------------------------------------------------------------------------------- Multiplex set Gene Mutation PCR product size ----------------------------------------------------------------------------------------------------- Set 1 (4ea primer) GJB2 V37I/235delC 416 bp R143W 311 bp Set 2 (2ea primer) mtRNR-1 A1555G 137 bp Set 3 (6ea primer) SLC26A4 IVS7-2A>G 363 bp IVS9+3A>G 301 bp H723R 227 bp ----------------------------------------------------------------------------------------------------- B, Target-specific primer sequences ----------------------------------------------------------------------------------------------------- Name 5' ➝ 3' sequence Gene (mutation) ----------------------------------------------------------------------------------------------------- GJB2-1_F1 TCTTTTCCAGAGCAAACCGC GJB2 (V37I/235delC) GJB2-1_R3 GATGCGGACCTTCTGGGTTT GJB2-2_F2 CTGCAGCTGATCTTCGTGTC GJB2 (R143W) GJB2-2_R2 ACAAAGCAGTCCACAGTGTT mtDNA_F1 CGTCACCCTCCTCAAGTATACTTC MTRNR1 (A1555G) mtDNA_R1 GCTTTGTGTTAAGCTACACTCTGG SLC-e7_F4 CAAAATCCCAGTCCCTATTCCTA SLC26A4 (IVS7-2A>G) SLC-e7_R4 GGTTGTTTCTTCCAGATCACACAC SLC-e9_F3 GCTTGTTCTCGGAGATGCTG SLC26A4 (IVS9+3A>G) SLC-e9_R1 AGTGATGCAGTGTGTCTATTCC SLC-e19_F1 CCTGGGCAATAGAATGAGACTC SLC26A4 (H723R) SLC-e19_R1 AAATGGAACCTTGACCCTCTTG -----------------------------------------------------------------------------------------------------
Results
Seven different mutations in three genes were successfully amplified by multiplex PCR (Fig. 3A) . Representative results of the HL genotyping microarray are shown in Fig. 3B . To standardize genotype assignment, we set cutoff values for each tested mutation based on the previous study to discriminate the different genotypes in the 51 subjects that had been previously genotyped by DNA sequencing (15) . To evaluate the accuracy of the HL genotyping microarray, 65 HL patients for whom genotyping information was unknown were examined in a blind test by both microarray and DNA sequencing (Table II) .
Mutant alleles were identified in 10 patients by microarray: three patients were homozygous for the GJB2 c.235delC mutation; four were heterozygous for the GJB2 c.235delC mutation; one was heterozygous for the p.V37I mutation; one was homozygous for the SLC26A4 IVS7-2A>G mutation; and one was heterozygous for the SLC26A4 p.H723R mutation. When the microarray results were compared with those obtained by DNA sequencing, one patient who had been genotyped as homozygous for the SLC26A4 IVS7-2A>G mutation in the microarray was revealed to be heterozygous for this mutation by DNA sequencing, indicating a false positive signal. One subject had an additional mutation (176-191del16) in the GJB2 gene, which was not included in the current panel. Overall, the accuracy of the microarray was calculated as 98% (64/65). Moreover, similar to the results of previous studies using DNA sequencing (7), the c.235delC mutant allele accounted for ~8% of the total alleles. Table II . Continued. 
Unmatched sample compare with chip screening and DNA sequencing data.
Discussion
Congenital HL is one of the most common inherited disorders, and at least 50% of cases are genetic in origin (20) . Early diagnosis of the genetic etiology of congenital HL expedites early intervention and aids in management decisions and genetic counseling. Moreover, studies suggest that early identification of HL helps children develop better language, cognitive and social skills when intervention occurs by six months of age, which is a significant improvement over infants diagnosed later (21) . During the last 15 years, major achievements have been made in the identification of deafness genes. However, clinical applications have lagged due to the genetic heterogeneity of the disease. To date, conventional gel-based and direct sequencing techniques have been used to screen known deafness genes, but extensive screening of all known genes involved in the development of deafness is very expensive and time-consuming. As certain mutations have been shown to be recurrent in populations, a screening strategy focusing on frequently recurring mutations could be a breakthrough for clinical applications.
Microarray approaches have been used extensively for analyzing the expression levels of thousands of genes and for performing multiplex genotyping of SNPs and large-scale mutation screening. For HL, several studies using microarrays have proposed high-throughput techniques for screening mutations in deafness genes and have demonstrated accurate and reliable results (19, 22, 23) . As some mutations on the mutation panels have only been identified in Caucasians or in other specific populations, genetic screening based on the mutation spectrum of a specific population may be an appropriate and effective strategy for detecting mutations in causative genes.
As a first step in the establishment of efficient and rapid genetic screening in Koreans, we developed and tested an HL genotyping microarray for simultaneous, multi-gene mutation screening of deaf patients. Since most genetic studies in the Korean population have been focused on the GJB2, SLC26A4 and mitochondrial genes, we selected seven different mutations in these genes based on their high frequencies in the Korean population (6) (7) (8) 10, (16) (17) (18) . The carrier frequency of the GJB2 gene is estimated to be 3% in the Korean population, and the p.V37I, c.235delC and p.R143W mutations were frequently found in Korean patients (6, 7, 17) . The SLC26A4 gene, which is associated with enlarged vestibular aquaducts (EVA), is also a common causative gene of HL. Park et al (2005) demonstrated that 20 (83%) out of 24 probands with SLC26A4 mutations had at least one of three recurrent mutations (p.H723R, IVS7-2A>G or IVS9+3A>G) (15, 18, 24, 25) . In addition, the mtDNA A1555G mutation has been identified as the most prevalent mitochondrial mutation associated with HL in the Korean population. No mutations were identified in the other tRNA genes associated with non-syndromic HL (16) .
The results of the tests for validation of the current version of HL genotyping microarray were fully concordant with those of sequencing analysis. Furthermore, the blind test of the genotyping microarray detected four different mutations in 10 out of 65 patients. A mutation in one subject was subsequently identified as a false positive. The most frequent mutations, c.235delC, IVS7-2A>G and p.H723R, were identified only in the blind testing. The frequency of GJB2 mutations detected by the genotyping microarray was 4% (3/65), similar to the results obtained by Park et al (7) . Our results suggest that this HL genotyping microarray will be useful in clinical applications for the genetic diagnosis of HL.
There are some limitations of this study. First, we need to include a wider range of different genotyping combinations. Most of the mutations in this study were frequently found in Korean patients affected by HL. Recently, a number of novel mutations were identified in the same population studied here, and some of the mutations, such as p.T86R and p.T123N in GJB2 and p.M147V and p.T721M in SLC26A4, were recurrent. Second, a larger number of patient samples of varied quality should be analyzed to ensure the accuracy of the microarray. For example, it is important to note that genomic DNA from newborns is primarily extracted from buccal swabs of the cheek, which suggests that the DNA concentration is low. Therefore, although more mutations will be included in the content of microarray, we also need to optimize the conditions of the multiplex PCR to amplify all of the products with similar accuracy.
In summary, we successfully designed a chip-based genotyping strategy according to the principles of the single nucleotide ASPE reaction and were able to simultaneously screen for seven mutations in three causative genes of HL. This chip-based assay will provide a relatively rapid and costeffective means of detecting mutations for clinical genetic diagnosis of HL.
